Antigenic GM-CSF peptides and antibodies to GM-CSF

US10023632B2 · kind B2 · utility

Assignee

• MORPHOTEK, INC. · US

Inventors

• Philip M. Sass · Audubon, US
• Nicholas C. Nicolaides · Boothwyn, US
• Luigi Grasso · Via Enrico Fermi, US
• Wolfgang Ebel · Conshohocken, US
• Jian Li · Fort Washington, US
• Qimin Chao · Havertown, US
• Eric Routhier · Glen Mills, US

Key dates

• Filing date: Jul 18, 2016
• Grant date: Jul 17, 2018
• Expiry date: Sep 1, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided. The antibodies may be used in therapeutic methods, for example in the treatment of cancer, infectious disease, or autoimmune disease.